Medidata Solutions Announces Parexel Has Joined Aspire to Win Program

Medidata Solutions, a global provider of electronic clinical data
capture (EDC), management and reporting solutions, today announced
that PAREXEL International, a leading global biopharmaceutical
services organization, has joined Medidata´s ASPire to Win(TM)
program, a non-exclusive application service provider (ASP)
partnership and business model. Through this program, Medidata will
provide tools and training to enable PAREXEL to implement Medidata
Rave(R) as an EDC solution for its global client base.

"PAREXEL has provided EDC-driven solutions for our clients´
clinical development programs for more than a decade. EDC is now a key
component of a total eClinical solution that we believe will help the
biopharmaceutical industry realize greater improvements in efficiency
and data quality in clinical studies," said Mark A. Goldberg, M.D.,
President of Clinical Research Services and Perceptive Informatics at
PAREXEL. "Medidata´s EDC solution has demonstrated increasing traction
in the marketplace with our client base, across all phases of clinical
research. This program will further strengthen our knowledge of
Medidata Rave technology and our ability to incorporate it as
appropriate into clinical studies."

PAREXEL decided to formalize its relationship with Medidata by
joining the ASPire to Win program. The program enables PAREXEL to
globally manage clinical trials using Medidata Rave. PAREXEL´s
selection of Medidata Rave was driven by the product´s broad user
acceptance, easy and fast deployment capability and key features
including real-time access to clinical data.

"We are excited to see PAREXEL take advantage of our ASPire to Win
program, which continues to expand with the industry´s increased
adoption of Medidata Rave," said Tarek Sherif, CEO of Medidata
Solutions. "With this alliance, PAREXEL will be able to help its
clients conduct clinical trials more efficiently. In addition, our
clients will have access to PAREXEL´s in-depth expertise in clinical
development, experience conducting thousands of studies and access to
a wide array of geographical locations in which to conduct clinical
research."

About PAREXEL International

PAREXEL International is a leading global bio/pharmaceutical
services organization, providing a broad range of knowledge-based
contract research, medical communications and consulting services to
the worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to clinical
pharmacology, clinical trials management, medical education and
reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL,
provides advanced technology solutions, including medical imaging, to
facilitate the clinical development process. Headquartered near
Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51
countries around the world, and has approximately 7,000 employees. For
more information about PAREXEL International visit www.PAREXEL.com.

About Medidata Solutions Worldwide

Medidata Solutions helps the world´s leading pharmaceutical,
biotechnology, medical device and research organizations maximize the
value of their clinical research investments. Innovative process
design, technology and services streamline clinical trials by
providing early visibility to reliable clinical data - the lifeblood
of every research organization. Working with companies and
institutions both large and small, Medidata Solutions helps clinical
researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80
countries. Medidata Solutions brings significant value to its broad
client base with deep clinical experience and expertise in more than
20 therapeutic areas, projects in Phase I, II, III, IV, registries and
surveillance, and studies with thousands of investigators and
tens-of-thousands of subjects. For more information, please visit
www.mdsol.com.